Astellas has established a strong presence in the urology area with Harnal®, a treatment for functional symptoms of benign prostatic hyperplasia, as well as overactive bladder treatments Vesicare® and Betanis®/Myrbetriq®/BETMIGA®. We are advancing clinical development by targeting urologic disorders with high unmet medical needs such as Nocturia, Stress urinary incontinence and Underactive bladder.


In nephrology, as a next-generation main product, we are advancing Phase 3 trials of roxadustat in Europe and Japan for anemia associated with chronic kidney disease in patients on dialysis and not on dialysis. In addition, moving forward we will work to develop first-in-class therapies for diabetic nephropathy and continue to challenge other kidney disorders with high unmet medical needs through the drug discovery research focusing on damage for glomerular and renal tubular epithelial cell in kidney.